PureTech Health PRTC Stock
PureTech Health Price Chart
PureTech Health PRTC Financial and Trading Overview
| PureTech Health stock price | 17.25 USD |
| Previous Close | 17.25 USD |
| Open | 17.44 USD |
| Bid | 17.89 USD x 100 |
| Ask | 15.7 USD x 100 |
| Day's Range | 17.25 - 17.25 USD |
| 52 Week Range | 14.5 - 19.92 USD |
| Volume | 6.76K USD |
| Avg. Volume | 9.19K USD |
| Market Cap | 419.9M USD |
| Beta (5Y Monthly) | 0.788 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.6 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PRTC Valuation Measures
| Enterprise Value | 4.14B USD |
| Trailing P/E | N/A |
| Forward P/E | -34.5 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 90.12586 |
| Price/Book (mrq) | 1.3361735 |
| Enterprise Value/Revenue | 889.38 |
| Enterprise Value/EBITDA | -42.793 |
Trading Information
PureTech Health Stock Price History
| Beta (5Y Monthly) | 0.788 |
| 52-Week Change | -0.21% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 19.92 USD |
| 52 Week Low | 14.5 USD |
| 50-Day Moving Average | 16.94 USD |
| 200-Day Moving Average | 17.21 USD |
PRTC Share Statistics
| Avg. Volume (3 month) | 9.19K USD |
| Avg. Daily Volume (10-Days) | 7.83K USD |
| Shares Outstanding | 24.34M |
| Float | 157.18M |
| Short Ratio | 3.94 |
| % Held by Insiders | 0% |
| % Held by Institutions | 0.57% |
| Shares Short | 24.52K |
| Short % of Float | 0.11% |
| Short % of Shares Outstanding | 0.10% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1797.79% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -10.81% |
| Return on Equity (ttm) | -30.85% |
Income Statement
| Revenue (ttm) | 4.66M USD |
| Revenue Per Share (ttm) | 0.19 USD |
| Quarterly Revenue Growth (yoy) | -38.20% |
| Gross Profit (ttm) | -51796000 USD |
| EBITDA | -96830000 USD |
| Net Income Avi to Common (ttm) | -109739000 USD |
| Diluted EPS (ttm) | -4.6 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 288.72M USD |
| Total Cash Per Share (mrq) | 1.19 USD |
| Total Debt (mrq) | 203.26M USD |
| Total Debt/Equity (mrq) | 66.49 USD |
| Current Ratio (mrq) | 6.587 |
| Book Value Per Share (mrq) | 12.91 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -85131000 USD |
| Levered Free Cash Flow (ttm) | -89990376 USD |
Profile of PureTech Health
| Country | United States |
| State | MA |
| City | Boston |
| Address | 6 Tide Street |
| ZIP | 02210 |
| Phone | 617 482 2333 |
| Website | https://www.puretechhealth.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Q&A For PureTech Health Stock
What is a current PRTC stock price?
PureTech Health PRTC stock price today per share is 17.25 USD.
How to purchase PureTech Health stock?
You can buy PRTC shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for PureTech Health?
The stock symbol or ticker of PureTech Health is PRTC.
Which industry does the PureTech Health company belong to?
The PureTech Health industry is Biotechnology.
How many shares does PureTech Health have in circulation?
The max supply of PureTech Health shares is 24.34M.
What is PureTech Health Price to Earnings Ratio (PE Ratio)?
PureTech Health PE Ratio is now.
What was PureTech Health earnings per share over the trailing 12 months (TTM)?
PureTech Health EPS is -4.6 USD over the trailing 12 months.
Which sector does the PureTech Health company belong to?
The PureTech Health sector is Healthcare.
PureTech Health PRTC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}